Zobrazeno 1 - 10
of 21
pro vyhledávání: '"David F. Claxton"'
Autor:
Charyguly Annageldiyev, Nicole R. Keasey, Emily Sullivan, Paul T. Toran, Hong Gang Wang, Regina M. Ondrasik, Su Fern Tan, Andrea L. Cote, Tye G. Deering, Todd E. Fox, David J. Feith, Brian M. Barth, Timothy J Brown, Stephan T. Stern, Mark Kester, David F. Claxton, Thomas P. Loughran, Vasiliki Papakotsi, Arati Sharma, Ross L. Levine, David B. Needle, Junjia Zhu, Sriram S. Shanmugavelandy, Aaron D. Viny, Viola Devine, Weiyuan Wang, Jason Liao
Publikováno v:
Blood Advances. 3:2598-2603
Key Points Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.
Autor:
Pau Montesinos, Farhad Ravandi, Martha Arellano, Karen Seiter, Ellin Berman, Jessica K. Altman, Lori J. Maness, Donald P. Quick, Parameswaran Venugopal, Judy H. Chiao, Scott R. Solomon, Rakesh Gaur, Mikkael A. Sekeres, Maria R. Baer, Marc Buyse, Aleksandra Butrym, David A. Rizzieri, Stephen A. Strickland, Stuart L. Goldberg, Tapan M. Kadia, Marc Gautier, David F. Claxton, Gary J. Schiller, Gianluca Gaidano, Kebede H. Begna, Selina M. Luger, Hagop M. Kantarjian, Xavier Thomas
Publikováno v:
Cancer
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alt
Autor:
John C. Grecula, Michaela Liedtke, Kristina Laumann, Guido Marcucci, Richard A. Larson, Wendy Stock, Noreen Fulton, Mark R. Litzow, Selina M. Luger, Martin S. Tallman, Jeffrey A. Bogart, Greg Malnassy, Krzysztof Mrózek, Richard Stone, Frederick R. Appelbaum, Matthew C. Foster, Edy Parker, Anjali S. Advani, Ben L. Sanford, Jun Yin, Charles G. Mullighan, Susan Geyer, Elisabeth Paietta, Richard C. Harvey, Harry P. Erba, Clara D. Bloomfield, Cheryl L. Willman, David F. Claxton
Publikováno v:
Blood. 133:1548-1559
Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address th
Autor:
Shin Mineishi, Christopher Ehmann, David F. Claxton, Valerie I. Brown, Neal Shah, Witold B. Rybka, Joseph Mierski, Gina Mackey, Hong Zheng, Myles Nickolich, Seema Naik, Kentaro Minagawa, Baldeep Wirk, Robert J. Greiner, Kevin Rakszawski, Brooke Silar
Publikováno v:
Annals of hematology. 100(10)
Acute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or
Autor:
L. Gashonia, Pavel Kiselev, Kaitlin Kennard, Christina Howlett, Allison M. Winter, Andre Goy, Clive S. Zent, Danielle M. Brander, Stephen J. Schuster, Chadi Nabhan, Kenneth A. Foon, Allan-Louie Cruz, Catherine Daniel, David F. Claxton, Brian T. Hill, Alan P Skarbnik, Paul M. Barr, Colleen Timlin, K. Isaac, Nicole Lamanna, Molly Fanning, Chaitra S. Ujjani, J. Lenhart, Melissa Yacur, Bruce D. Cheson, Jeffrey J. Pu, Jakub Svoboda, S. Henick Bachow, Anthony R. Mato
Publikováno v:
Annals of Oncology. 28:1050-1056
Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence.We conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhib
Autor:
Sunita D. Nasta, Jakub Svoboda, Pavel Kiselev, Tatyana Feldman, Paul M. Barr, Daniel Porter, Jeffrey J. Pu, Nicole Lamanna, David F. Claxton, Clive S. Zent, Chadi Nabhan, Alison R. Sehgal, Gurbakhash Kaur, Andrew M. Evens, Spencer Henick Bachow, Anthony R. Mato, Bruce D. Cheson, Andre Goy, Lauren E. Strelec, Chaitra S. Ujjani, Daniel J. Landsburg, Alexandra Vandegrift, Stephen J. Schuster, Danielle M. Fitzpatrick, Brian T. Hill, Alan P Skarbnik, Christina Howlett
Publikováno v:
Blood. 128:2199-2205
B-cell receptor kinase inhibitor (KI) therapy represents a paradigm shift in chronic lymphocytic leukemia (CLL) management, but data on practice patterns after KI discontinuation and optimal sequencing are limited. We conducted a multicenter, retrosp
Autor:
Kosuke Miki, Kevin Rakszawski, Shin Mineishi, Seema Naik, Henry N. Wagner, David F. Claxton, Hiroko Shike
Publikováno v:
International Journal of Hematology. 108:348-350
Approximately 30-40% of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent i
Autor:
Bei, Jia, Chenchen, Zhao, Kevin L, Rakszawski, David F, Claxton, W Christopher, Ehmann, Witold B, Rybka, Shin, Mineishi, Ming, Wang, Hiroko, Shike, Michael G, Bayerl, Jeffrey M, Sivik, Todd D, Schell, Joseph J, Drabick, Raymond J, Hohl, Hong, Zheng
Publikováno v:
Cancer research. 79(7)
Acute myeloid leukemia (AML) is a devastating blood cancer with poor prognosis. Immunotherapy targeting inhibitory pathways to unleash the antileukemia T-cell response is a promising strategy for the treatment of leukemia, but we must first understan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:41-46
Background Clofarabine, a second-generation nucleoside analogue, was studied in combination with etoposide and mitoxantrone in acute leukemia. Patients and Methods In the phase I portion of this study clofarabine was given 20 or 25 mg/m2 daily for 5
Publikováno v:
Leukemialymphoma. 57(6)
This study investigated whether initial respiratory status in hyperleukocytic acute myeloid leukemia (AML), as defined by oxygen/ventilatory support, is (1) associated with early mortality and overall survival and (2) improved after leukapheresis. A